Nasacort AQ Switch Rides On “Evolution Of Data” – Sanofi CMO
This article was originally published in The Tan Sheet
Executive Summary
Charles Hugh-Jones, Sanofi’s chief medical officer for North America, says the firm will present clinical and consumer use data to allay concerns about the safety of intranasal corticosteroids, at the upcoming FDA advisory committee meeting to discuss the Rx-to-OTC switch of Nasacort AQ.